Ισραήλ - Εβραϊκά - Ministry of Health

gilco pharm ltd. - כלל האוכלוסיה - טיפול והקלה בגירויים בחלל הפה והגרון, יובש בפה

Ισραήλ - Εβραϊκά - Ministry of Health

gilco pharm ltd. - כלל האוכלוסיה - קרם טיפולי למצבי אקזמה, קסרוזיס, היפרקרטוזיס, אדמומיות, עור קשקשי ומונע יובש ברגליים לחולי סוכרת

Ισραήλ - Εβραϊκά - Ministry of Health

gilco pharm ltd. - כלל האוכלוסיה - משמיד כינים ומסייע למניעה ולסילוק ביצי כינים

Ισραήλ - Εβραϊκά - Ministry of Health

gilco pharm ltd. - כלל האוכלוסיה - לטיפול במצבי יובש כולל היפרקרטוזיס, אקזמה, אטופיק דרמטיטיס, עור מגורה, גרד

Ισραήλ - Εβραϊκά - Ministry of Health

gilco pharm ltd. - כלל האוכלוסיה - לטיפול ומניעה של יובש, גודש, פצעים ודימומים בחלל ואזור האף

Ισραήλ - Εβραϊκά - Ministry of Health

gilco pharm ltd. - כלל האוכלוסיה - תמיסת סלאיין סטרילית

Ισραήλ - Εβραϊκά - Ministry of Health

gilco pharm ltd. - כלל האוכלוסיה - ג'ל לטיפול והקלה

Ισραήλ - Εβραϊκά - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

Ισραήλ - Εβραϊκά - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

Ισραήλ - Εβραϊκά - Ministry of Health

abbott medical laboratories ltd - niacin 1000 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n